SCHEMBL2926003

SCHEMBL2926003

CCN(CC)c1ccc2nc(Nc3cc(F)ccc3F)[nH]c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 2/20 0.43
KMT2A Q03164 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
NPC1 O15118 2/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
TCF4 P15884 1/20 0.43
CTNNB1 P35222 1/20 0.43
SYK P43405 1/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
KDR P35968 2/20 0.41
TEK Q02763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932965 0.91 MAPT (0.41) SMN1; SMN2LMNAMAPTNPSR1KDM4E
SCHEMBL2929609 0.81 MEN1 (0.46) SMN1; SMN2LMNAMAPTNPSR1KDM4E
SCHEMBL14693632 0.81 KDR (0.41) MAPTHTTPOLBGAAKDR
SCHEMBL14693564 0.81 KDR (0.41) MAPTHTTPOLBGAAKDR
SCHEMBL2925719 0.81 MEN1 (0.47) SMN1; SMN2LMNAMAPTNPSR1KDM4E
SCHEMBL2930206 0.80 RAB9A (0.43) SMN1; SMN2LMNAMAPTNPSR1KDM4E
SCHEMBL2932187 0.79 LMNA (0.64) SMN1; SMN2LMNAMAPTNPSR1KDM4E
SCHEMBL2931537 0.78 POLB (0.53) SMN1; SMN2LMNAMAPTNPSR1KDM4E
SCHEMBL2932290 0.77 MAPT (0.47) SMN1; SMN2LMNAMAPTNPSR1KDM4E
SCHEMBL2931162 0.72 SMN1; SMN2 (0.44) SMN1; SMN2LMNAMAPTNPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820821-B2 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors TRANSTECH PHARMA, INC. (US) 2010-06-17 US disclosed
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors VTVX HOLDINGS I LLC 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors AURKC, AURKA, AURKB SMN1; SMN2 4734/4885LMNA 1520/4885MAPT 1464/4885
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors AURKC, AURKA, AURKB SMN1; SMN2 4734/4885LMNA 1520/4885MAPT 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.